Orchestra BioMed presents Virtue SAB at TCT symposium
OBIO•Orchestra BioMed will present Virtue SAB at TCT 2026 in San Diego, where Allen Jeremias is scheduled to discuss the balloon’s drug-delivery mechanism, clinical evidence and pivotal trial design. The enrolling Virtue Trial targets approximately 740 patients, comparing Virtue SAB with the AGENT paclitaxel-coated balloon for coronary in-stent restenosis.
1. TCT presentation and trial
Allen Jeremias is scheduled to present Virtue SAB on Nov. 1, 2026, from 9:03 to 9:10 a.m. PT at TCT 2026, running Oct. 31-Nov. 3 at the San Diego Convention Center. The enrolling Virtue Trial targets approximately 740 patients and compares Virtue SAB with the AGENT paclitaxel-coated balloon for coronary in-stent restenosis.
